PARPi Response Prediction with Pillar Biosciences’ oncoReveal Geentic and Epigenetic Alteration Panels
Event Name: AMP 2021
TBC
Utilizing Pillar Biosciences’ Rapid oncoReveal 4-Gene Methylation Panel to Guide PARPi Therapy in Breast Cancer Patients
Event Name: AMP 2024
TBC
Looking Deeper into HRD to Inform PARP Inhibitor Therapy: Building the Case for NGS Methylation Testing
Publishing Entity: GenomeWeb | Precision Medicine Online
Assessment of Homologous Repair Deficiency status in Triple Negative Breast and Ovarian Carcinoma using Genetic and Epigenetic Next Generation Sequencing Assays
Temple University Hospital and Fox Chase Cancer Center paired Pillar’s oncoReveal® HRDv2 mutation panel with a quantitative oncoReveal® methylation assay to assess homologous recombination deficiency (HRD) — the phenotype predicting PARP inhibitor response — in retrospective ovarian and triple negative breast cancer (TNBC) specimens. Seventy-one FFPE samples (43 ovarian, 28 TNBC) were microdissected and tested for both pathogenic variants and BRCA1, RAD51C, and XRCC3 promoter hypermethylation on the Illumina MiSeq with PiVAT® analysis. Pathogenic HRD mutations appeared in 56 of 71 specimens (79%), and methylation flagged additional HRD-positive cases that mutation testing alone would have missed.